U.S. Food and Drug Administration (FDA) · United States
FDA Healthcare Social Media Marketing
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)
What is FDA Healthcare Social Media Marketing?
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information. Rx drug and restricted device social posts, videos, stories and paid influencer content on any platform.
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
How can marketing teams comply?
Rx drug and restricted device social posts, videos, stories and paid influencer content on any platform.
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.
Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.
FDA's food labeling rules require a Nutrition Facts panel and other label elements and restrict nutrient and 'healthy' claims to foods meeting FDA criteria; the amended 'healthy' definition is effective April 28, 2025 with compliance required by Feb. 25, 2028.
Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Request a free compliance scan of your homepage and book a time with Warrant.